Mts Medication Technologies, Inc /DE/ - Current report filing (8-K)
February 07 2008 - 3:10PM
Edgar (US Regulatory)
United States
Securities and
Exchange Commission
Washington D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): February 7, 2008
|
MTS Medication Technologies, Inc.
|
|
|
|
|
|
(Exact Name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-31578
|
|
59-2740462
|
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
|
2003 Gandy Boulevard North,
Suite 800, St. Petersburg, Florida 33702
|
|
|
|
|
|
(Address of principal executive offices) (Zip Code)
|
|
(Registrant's telephone
number, including area code):
(727) 576-6311
|
N/A
|
|
|
|
|
|
(Former name or former address, if changed since last report)
|
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-42(c))
Item 2.02 Results of
Operations and Financial Condition.
On
February 6, 2008, MTS Medication Technologies, Inc. (MTS) issued a press
release announcing its results of operations for the third quarter and nine months ended
December 31, 2007. A copy of the press release is furnished as Exhibit 99.1 to this
Report and is incorporated into this Report by reference.
The
information in this Form 8-K is being furnished and shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section. The information contained in this
Form 8-K and in the accompanying exhibit shall not be incorporated by reference into any
registration statement or other document filed with the Securities and Exchange Commission
by MTS, whether made before or after the date hereof, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by specific
reference in such filing.
Item 7.01 Regulation FD
Disclosure
The
information set forth under Item 2.02 of this Report on Form 8-K is hereby incorporated in
this Item 7.01 by reference.
Item 9.01
Financial Statements and Exhibits
(c)
Exhibits.
|
EXHIBIT
|
|
DESCRIPTION
|
|
|
|
|
|
|
|
99.1
|
|
Press Release of MTS Medication Technologies, Inc., dated February 6, 2008
related to the third quarter and nine months ended December 31, 2007* (furnished pursuant to Item 2.02).
|
|
*Such information is being
furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
MTS Medication Technologies, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
Date: February 7, 2008
|
|
|
|
|
|
|
|
By:
|
/s/ Michael P. Conroy
|
|
|
|
|
|
|
|
|
|
|
|
Michael P. Conroy
|
|
|
|
|
|
|
|
|
|
|
|
Vice President and Chief Financial Officer
|
|
|
2
Mts Medications (AMEX:MPP)
Historical Stock Chart
From May 2024 to Jun 2024
Mts Medications (AMEX:MPP)
Historical Stock Chart
From Jun 2023 to Jun 2024